Respiratorius is a research company focused on the development of drug candidates for the treatment of cancer, and especially aggressive lymphoma. The company was established in 1999 as a spin-off from Lund University. The operations are located in Sweden, where research is conducted in-house, but also through international partners. The company has its headquarters in Lund.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Avanza Pension | 8,31 | 8,31 | 2025-12-23 |
| Hans Mandahl | 4,05 | 4,05 | 2025-12-23 |
| Valcuria Holding AB | 3,70 | 3,70 | 2025-12-23 |
| Hartmut Wiese | 2,53 | 2,53 | 2025-12-23 |
| Ulf Stahlin | 1,21 | 1,21 | 2025-12-23 |
| Erik Boström | 1,21 | 1,21 | 2025-12-23 |
| Håkan Svensson | 1,14 | 1,14 | 2025-12-23 |
| Per Vasilis | 1,11 | 1,11 | 2025-12-23 |
| Gerhard Dal | 1,11 | 1,11 | 2025-12-23 |
| Christian Müller | 1,06 | 1,06 | 2025-12-23 |
2026-05-26 Interim Report 2026-Q1
2026-06-09 Annual General Meeting 2025
2026-08-11 Interim Report 2026-Q2
2026-11-10 Interim Report 2026-Q3
2027-02-09 Year End Report 2026
